GEA Group Reaffirms 2026 Outlook as Order Intake Set to Top €6 Billion

Key Points

• GEA reaffirmed its raised 2026 outlook, targeting 6%–8% organic sales growth, a 17%–17.4% EBITDA margin before restructuring costs, and 36%–40% return on capital employed.
• Order momentum remains strong, with full-year order intake expected to exceed €6 billion, supported by large projects and healthy base-order demand across food, beverage, dairy, and pharmaceutical markets.
• Management expects continued profitability improvement and a backlog up more than 13% to support growth through 2027 and potentially 2028, while 2026 free cash flow is forecast at roughly €500 million.

GEA Group Aktiengesellschaft ETR: G1A reaffirmed its raised 2026 financial guidance ahead of its third-quarter results, citing continued strength in order intake, favorable demand across several customer industries and expected further profitability improvement.

Speaking on the company’s third-quarter pre-close call, Head of Investor Relations Oliver Luckenbach said GEA continues to expect organic sales growth of 6% to 8% for the full year, an EBITDA margin before restructuring expenses of 17% to 17.4%, and return on capital employed of 36% to 40%.

Order intake expected to exceed €6 billion

Luckenbach said management expects another strong year for orders, supported by a promising project pipeline and healthy base-order activity. The company reported organic order intake growth of 10.7% in the first half of 2026 and said it saw no reason that momentum would not have continued in the third quarter.

GEA recorded several large orders—defined as orders above €15 million—with a combined volume in the low triple-digit millions of euros during the third quarter, according to Luckenbach. By comparison, the third quarter of 2025 included three large orders totaling €64 million.

“All we can see as of today is also another strong quarter also for order intake,” Luckenbach said in response to an analyst question, adding that the company expects full-year order intake to exceed €6 billion. GEA reported €5.9 billion of order intake in 2025.

The company noted that fourth-quarter comparisons will be demanding. GEA recorded €1.8 billion in order intake in the fourth quarter of 2025, including more than €400 million in large orders.

Luckenbach said base-order demand remained healthy across the company’s businesses, while cautioning that detailed third-quarter figures were not yet available. He said GEA had not seen a meaningful disruption or downward trend in lower order categories.

Food, beverage, dairy and pharma markets supportive

GEA said food markets were broadly favorable, with particular strength in poultry projects. Beverage activity was also strong, especially in project business, while dairy processing continued to show activity in both projects and components.

Demand for protein-rich products remains one driver in dairy processing, and Luckenbach said GEA expects that trend to continue for the next two years or so. In dairy farming, management described market sentiment as “okay,” with good demand particularly from larger farms.

During the question-and-answer session, Luckenbach said dairy-farming conditions remained positive overall, pointing to healthy milk-to-feed price ratios in most of the regions where GEA operates. While smallholder farmers can be affected by changes in subsidies, he said there had been no significant new market development since the first half.

Pharmaceutical markets also continue to look favorable. Deputy Head of Investor Relations Rebecca Weigl said demand for the company’s continuous tablet presses has benefited from an innovation that enables continuous rather than batch-based manufacturing. She added that the potential transition of GLP-1 products into oral tablet form could create an additional future opportunity.

Luckenbach said chemicals was not among GEA’s major focus customer industries and acknowledged it may not currently be the company’s strongest end market.

Sales, margins and backlog

GEA generated 8.2% organic sales growth in the first half of 2026. For the third quarter, Luckenbach said the company’s 6% to 8% full-year sales-growth guidance was “probably also a range for Q3,” despite tougher comparisons in the second half.

The company reported an EBITDA margin before restructuring expenses of 16.8% in the first half. Luckenbach said GEA expects further margin progress in the third quarter, compared with a 17.0% margin in the prior-year quarter, as sales growth supports operating leverage.

GEA’s backlog was up more than 13% at the end of the first half, according to Luckenbach. He said large orders, including the Baladna project, are expected to support revenue growth not only in 2026 but also in 2027 and potentially 2028.

Cash flow and other financial items

GEA expects free cash flow for 2026 to be around the prior-year level of approximately €500 million. The company expects full-year capital expenditures of around €240 million, compared with €72 million in the first half, with spending set to increase in the second half.

Net working capital as a percentage of sales is expected to remain within GEA’s 7% to 9% target corridor in the third quarter. Luckenbach said customer prepayments could support cash flow, though he did not identify other major expected effects beyond previously discussed factors such as higher second-half capital expenditure.

• Expected 2026 depreciation and amortization before restructuring expenses: around €230 million.
• Expected 2026 financial result: negative €30 million.
• Expected 2026 tax rate: 28% to 30%.
• Expected 2026 R&D ratio: around 3%.
• Expected 2026 restructuring expenses: around €50 million.

GEA also said foreign-exchange effects are expected to be neutral to slightly positive, with no significant impact anticipated based on current conditions. As of Oct. 2, the company had repurchased 955,764 shares for an aggregate €62.5 million since launching its buyback program in August.

On its enterprise-resource-planning rollout, GEA said the implementation was proceeding according to plan. About 15% of sales are currently on the new platform, a figure expected to reach about one-quarter by the beginning of 2027. The company is scheduled to release third-quarter results on Nov. 9.

About GEA Group Aktiengesellschaft (ETR:G1A)

GEA Group Aktiengesellschaft engages in the development and production of systems and components to the food, beverage, and pharmaceutical industries. It operates through Separation & Flow Technologies, Liquid & Power Technologies, Food & Health Technologies, Farm Technologies, and Heating & Refrigeration Technologies segments. The Separation & Flow Technologies segment manufacture process-related components and machinery including notably separators, decanters, homogenizers, valves, and pumps.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.